Pharmacy Practice (Management and Marketing)
Topic: Portfolio of a Multinational Pharmaceutical
Industry
Submitted To: Mam Sidra Yasin
Submitted By: Group-10
10th - D
Zavyiear ali 70100164
Adeel shahid 70100271
Talha khalid 70098310
Omer yousaf 70097572
Mohamed samy 70097162
Portfolio of Highnoon Pharmaceutical Industry
1. Vision:
To be a global leader in providing innovative and affordable healthcare solutions.
2. Mission:
Highnoon Pharmaceutical Industry is dedicated to improving the quality of life by developing and
delivering high-quality, safe, and effective pharmaceutical products to meet the healthcare needs of
patients around the world.
3. Objective:
Develop and launch at least three new products within the next five years.
Expand market share in emerging markets by 15% over the next three years.
Achieve a 20% reduction in production costs through process optimization and efficiency
improvements within the next two years.
4. Policies:
I. Quality Policy:
Highnoon Pharmaceutical Industry is committed to providing high-quality products that meet or
exceed customer expectations and regulatory requirements.
II. Ethical Policy:
We conduct our business with the highest standards of integrity, ethics, and transparency.
III. Environmental Policy:
We are committed to minimizing our environmental impact through sustainable practices and
continuous improvement.
5. Strategies:
Short Term:
Increase marketing efforts for existing products to boost sales.
Enhance R&D investments to accelerate the development of new drugs.
Long Term:
Expand manufacturing facilities to meet growing demand.
Strengthen partnerships with healthcare providers and regulatory agencies.
6. Analysis (ARM/MRM):
Analysis of Risk Management (ARM):
Highnoon Pharmaceutical Industry conducts regular risk assessments to identify, evaluate, and
mitigate potential risks to the business, including regulatory compliance, supply chain disruptions,
and market competition.
Management Review Meetings (MRM):
These meetings are held periodically to review the company's performance, discuss strategic
issues, and make decisions to drive the business forward.
7. PDCA Cycle:
Highnoon Pharmaceutical Industry follows the Plan-Do-Check-Act (PDCA) cycle for continuous
improvement.
This involves planning new initiatives, implementing them, evaluating their effectiveness, and
making adjustments as necessary to achieve better results.
The PDCA includes:
I. Plan: Develop and refine strategic plans based on market trends, regulatory changes, and
emerging technologies.
II. Do: Implement the planned strategies and initiatives, ensuring alignment with organizational
goals.
III. Check: Regularly assess the performance and outcomes of implemented strategies through key
performance indicators (KPIs) and feedback mechanisms.
IV. Act: Adjust strategies, policies, and operations based on the evaluation results, continuously
improving and optimizing the business approach.
8. Crisis Management:
Highnoon Pharmaceutical Industry has a comprehensive crisis management plan in place to
effectively respond to emergencies such as product recalls, natural disasters, or public health
crises.
This plan includes clear roles and responsibilities, communication protocols, and strategies for
managing the impact on the business and stakeholders.
9. Risk Management:
Highnoon Pharmaceutical Industry proactively identifies, assesses, and manages risks that could
impact its business operations or reputation.
This includes financial risks, regulatory risks, operational risks, and strategic risks.
The company uses a variety of risk management tools and techniques to mitigate these risks,
including insurance, hedging, and contingency planning.
